Status:
UNKNOWN
Hyperemic Efficacy of IV Adenosine in HFrEF
Lead Sponsor:
Sejong General Hospital
Conditions:
Heart Failure With Reduced Ejection Fraction
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studi...
Detailed Description
Little is known about the hyperemic efficacy of IV adenosine as well as safety in patients with heart failure with reduced ejection fraction (HFrEF) because they were excluded from the major FFR studi...
Eligibility Criteria
Inclusion
- angiographically proven epicardial intermediate stenosis (40-70%)
- echocardiographically proven LV dysfunction (LVEF ≤40%)
Exclusion
- infarct-related artery, less than 2 weeks
- Killip class 3 and 4
- bronchial asthma
- second degree or third degree AV block
- any contraindications to adenosine
Key Trial Info
Start Date :
March 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2020
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT03235700
Start Date
March 1 2017
End Date
February 28 2020
Last Update
August 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sejong general hospital, 91-121 Sosa 2-Dong, Sosa-Gu
Bucheon-si, Gyeonggi-do, South Korea, 422-711